Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds Post published:April 19, 2022 Post category:Press Release
Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural Psilocybin Products Post published:April 19, 2022 Post category:Press Release
Psychedelic Bulletin: Numinus to Enter U.S. Clinics Market; Mydecine Announces Reverse Stock-Split; Are Magic Mushrooms Giving Investors a Bad Trip? Post published:April 15, 2022 Post category:Psychedelic Bulletin
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium Post published:April 14, 2022 Post category:Press Release
Numinus Wellness Inc. Reports Q2 2022 Results Post published:April 14, 2022 Post category:Press Release
Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT Post published:April 13, 2022 Post category:Press Release
Filament Health Is Issued Patent By United States Patent And Trademark Office Post published:April 13, 2022 Post category:Press Release
Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway Post published:April 13, 2022 Post category:Press Release
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs Post published:April 12, 2022 Post category:Press Release